<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02614287</url>
  </required_header>
  <id_info>
    <org_study_id>15770</org_study_id>
    <secondary_id>I5Q-MC-CGAJ</secondary_id>
    <secondary_id>2015-001884-38</secondary_id>
    <nct_id>NCT02614287</nct_id>
  </id_info>
  <brief_title>A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura</brief_title>
  <official_title>A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the longer term safety of the study drug known
      as galcanezumab in participants with episodic or chronic migraine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2015</start_date>
  <completion_date type="Actual">August 14, 2018</completion_date>
  <primary_completion_date type="Actual">May 12, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Discontinued Due to Adverse Event</measure>
    <time_frame>Baseline through Month 12</time_frame>
    <description>Adverse Event: Any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
A summary of other non-serious AEs, and all SAE's, regardless of causality, is reported in the Adverse Events section.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Galcanezumab</measure>
    <time_frame>Baseline through Month 12</time_frame>
    <description>Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Galcanezumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of Galcanezumab</measure>
    <time_frame>Month 12</time_frame>
    <description>Serum Concentrations of Galcanezumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP)</measure>
    <time_frame>Month 12</time_frame>
    <description>Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Developing Anti-Drug Antibodies to Galcanezumab</measure>
    <time_frame>Month 1 through Month 12</time_frame>
    <description>A Treatment Emergent Anti-drug Antibody (TE ADA) evaluable participant is considered to be TE ADA+ if the participant has at least one post-baseline titer that is a 4-fold or greater increase in titer from baseline measurement. If baseline result is ADA Not Present, then the participant is TE ADA+ if there is at least one post-baseline result of ADA Present with titer &gt;= 1: 20 (treatment-induced).
There were 6 participants in the 120 mg arm who discontinued after receiving loading dose of 240mg, these participants were moved to 240mg arm for safety analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Mean Change From Baseline in the Number of Migraine Headache Days (MHD)</measure>
    <time_frame>Baseline, Month 1 through Month 12</time_frame>
    <description>MHD: A calendar day on which a migraine headache or probable migraine headache occurred. Overall mean is derived from the average of months 1 to 12 from MMRM model. Least squares mean (LSMean) was calculated using mixed model repeated measures (MMRM) model with treatment, pooled investigative site, month, and treatment by month, baseline, and baseline by month as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Mean Change From Baseline in the Number of Headache Days</measure>
    <time_frame>Baseline, Month 1 through Month 12</time_frame>
    <description>Headache Day: A calendar day on which any type of headache occurred (including migraine, probable migraine, and non-migraine headache).
Overall mean is derived from the average of months 1 to 12 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled investigative site, month, and treatment by month, baseline, and baseline by month as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Overall Reduction From Baseline â‰¥50% in Monthly Migraine Headache Days</measure>
    <time_frame>Baseline, Month 1 through Month 12</time_frame>
    <description>Migraine Headache Day: A calendar day on which a migraine headache or probable migraine headache occurred.
Overall percentage of participants with a given response rate were estimated from the generalized linear mixed models (GLIMMIX) model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Mean Change From Baseline in the Frequency of Medication Use for the Acute Treatment of Migraines or Headaches</measure>
    <time_frame>Baseline, Month 1 through Month 12</time_frame>
    <description>Overall mean is derived from the average of months 1 to 12 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled investigative site, month, and treatment by month, baseline, and baseline by month as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Mean Patient Global Impression-Improvement (PGI-I) Score</measure>
    <time_frame>Month 1 through Month 12</time_frame>
    <description>The Patient Global Impression of Improvement (PGI -I) scale is a participant-rated instrument that measures the participants own global impression of their symptom improvement. The participant was instructed as follows: &quot;Mark the box that best describes your migraine headache condition since you started taking this medicine.&quot; Response options were on a 7-point scale in which a score of 1 indicates that the participant's condition is &quot;very much better,&quot; a score of 4 indicates that the participant has experienced &quot;no change,&quot; and a score of 7 indicates that the participant is &quot;very much worse.&quot; Overall mean is derived from the average of months 1 to 12 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled investigative site, month, and treatment by month, baseline PGI-S, and baseline PGI-S by month as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Mean Change From Baseline on the Migraine Disability Assessment Test (MIDAS) Total Score</measure>
    <time_frame>Baseline, Month 1 through Month 12</time_frame>
    <description>The MIDAS is a participant-rated scale which was designed to quantify headache-related disability over a 3-month period. This instrument consists of five items that reflect the number of days reported as missing or with reduced productivity at work or home, and the number of days of missed social events. Each item has a numeric response range from 0 to 90 days, if days are missed from work or home they are not counted as days with reduced productivity at work or home. The numeric responses are summed to produce a total score ranging from 0 to 270, in which a higher value is indicative of more disability. Overall mean is derived from the average of months 1 to 12 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled investigative site, month, and treatment by month, baseline, and baseline by month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Mean Change From Baseline on the Migraine-Specific Quality of Life Questionnaire (MSQ) Version 2.1</measure>
    <time_frame>Baseline, Month 1 through Month 12</time_frame>
    <description>MSQv2.1 is a health status instrument,with a 4-week recall period, developed to address physical &amp; emotional limitations of specific concern to individuals with migraine. Addressing the impact of migraine on work or daily activities, relationships with family &amp; friends, leisure time, productivity, concentration, energy, tiredness &amp; feelings.It consists of 14 items addressing 3 domains:(1)Role Function-Restrictive (items 1-7);(2)Role Function- Preventive (items 8-11);&amp;(3)Emotional Function (items 12-14).Response options range from &quot;none of the time&quot; (value 1) to &quot;all of the time&quot; (value 6), &amp; are reverse-recoded (value 6 to 1) before the domain scores are calculated. Total raw scores for each domain is the sum of the final item value for all of the items in that domain.After total raw score is computed for each domain &amp; total score, they are transformed to a 0-100 scale with higher scores indicating a better health status &amp; a positive change in scores reflecting functional improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Positive Responses on Patient Satisfaction With Medication Questionnaire-Modified (PSMQ-M)</measure>
    <time_frame>Baseline through Month 12</time_frame>
    <description>The PSMQ-M is a self-rated scale which measures participants level of satisfaction with study medication.The scale has been modified for use in this study, assessing 3 items related to the clinical trial treatment over the past 4 weeks: satisfaction, preference, and side effects. Satisfaction responses range from &quot;very unsatisfied&quot; to &quot;very satisfied&quot; with the current treatment. Preference compares the current study medication to previous medications, with responses from &quot;much rather prefer my previous medication&quot; to &quot;much rather prefer the medication administered to me during the study&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participant Visits With Positive Reponses by Device Type Subcutaneous Administration Assessment Questionnaire Q1, Q3-Q12</measure>
    <time_frame>Baseline through Month 12</time_frame>
    <description>The SQAAQ is a self-administered questionnaire that provides an assessment of ease of use and confidence with using a device to administer a subcutaneous injection of study drug. Participants will respond to questionnaire items using a 7-point Likert scale (from &quot;Strongly Disagree&quot; to &quot;Strongly Agree&quot;) shortly after the injection. If a caregiver administers the injection, the participants should be prepared to provide the caregiver's ratings of the questions.strongly agree &amp; agree are considered as positive responses.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">270</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Galcanezumab 120 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Galcanezumab 240mg given as loading dose at first dosing visit followed by 120 mg given by subcutaneous (SC) injection once a month for up to 11 months by auto injector or pre-filled syringe.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Galcanezumab 240 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Galcanezumab 240 mg given by SC injection once a month for up to 12 months by auto injector or pre-filled syringe.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galcanezumab</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Galcanezumab 120 mg</arm_group_label>
    <arm_group_label>Galcanezumab 240 mg</arm_group_label>
    <other_name>LY2951742</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of episodic or chronic migraine as defined by International Headache
             Society (IHS) International Classification of Headache Disorders (ICHD)-3 beta
             guidelines (1.1, 1.2 or 1.3) (ICHD-3 2013), with a history of migraine headaches of at
             least 1 year prior to screening, and migraine onset prior to age 50.

          -  Prior to baseline, a history of 4 or more migraine headache days per month on average
             for the past 3 months.

        Exclusion Criteria:

          -  Are currently enrolled in or have participated within the last 30 days or within 5
             half-lives (whichever is longer) in a clinical trial involving an investigational
             product.

          -  Current use or prior exposure to galcanezumab or another CGRP antibody.

          -  Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic
             proteins, or to galcanezumab.

          -  History of persistent daily headache, cluster headache or migraine subtypes including
             hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine
             with brainstem aura (basilar-type migraine) defined by IHS ICHD-3 beta.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Medical Clinic for Headache</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Encompass Clinical Research</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Institute for Clinical Research</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunrise Clinical Research</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Neurosciences</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PharmQuest</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilmington Health Associates</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suburban Research Associates</name>
      <address>
        <city>Media</city>
        <state>Pennsylvania</state>
        <zip>19063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinpoint Trial, LLC</name>
      <address>
        <city>Waxahachie</city>
        <state>Texas</state>
        <zip>75165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ericksen Research and Development</name>
      <address>
        <city>Clinton</city>
        <state>Utah</state>
        <zip>84015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blue Ridge Research Center</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Calgary</city>
        <zip>T3M 1M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Sherbrooke</city>
        <zip>J1H1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Toronto</city>
        <zip>M4S 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nice</city>
        <zip>6000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Esztergom</city>
        <zip>2500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gyor</city>
        <zip>9023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ponce School of Medicine CAIMED Center</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lillytrialguide.com/EN-US/studies/headache/cgaj</url>
    <description>Click here for more information about this study: A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 23, 2015</study_first_submitted>
  <study_first_submitted_qc>November 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2015</study_first_posted>
  <results_first_submitted>August 23, 2018</results_first_submitted>
  <results_first_submitted_qc>December 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 7, 2019</results_first_posted>
  <disposition_first_submitted>May 8, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>May 8, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 11, 2018</disposition_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prevention</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>headache</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 23, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT02614287/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 23, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT02614287/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Galcanezumab 120 mg</title>
          <description>Participants received a loading dose of 240 milligram (mg) galcanezumab at first dosing visit followed by120 mg galcanezumab once a month by subcutaneous injection during open label treatment phase. Participants did not receive any intervention during post treatment follow-up phase.</description>
        </group>
        <group group_id="P2">
          <title>Galcanezumab 240 mg</title>
          <description>Participants received 240 mg of galcanezumab once a month by subcutaneous injection during open label treatment phase. Participants did not receive any intervention during post treatment follow-up phase.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Open Label (OL) Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
                <participants group_id="P2" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
                <participants group_id="P2" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Post Treatment Follow-up Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="112">Follow-up period was optional, few participants who completed OL period didn't enter follow-up.</participants>
                <participants group_id="P2" count="124">Follow-up period was optional, few participants who completed OL period didn't enter follow-up.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>Galcanezumab 120 mg</title>
          <description>Participants received a loading dose of 240 mg galcanezumab at first dosing visit followed by 120 mg galcanezumab once a month by subcutaneous injection during open label treatment phase &amp; participants did not receive any intervention during post treatment follow-up phase.</description>
        </group>
        <group group_id="B2">
          <title>Galcanezumab 240 mg</title>
          <description>Participants received 240 mg galcanezumab once a month by subcutaneous injection during open label treatment phase &amp; participants did not receive any intervention during post treatment follow-up phase.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="135"/>
            <count group_id="B2" value="135"/>
            <count group_id="B3" value="270"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="135"/>
                    <count group_id="B2" value="135"/>
                    <count group_id="B3" value="270"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.21" spread="11.68"/>
                    <measurement group_id="B2" value="43.69" spread="10.99"/>
                    <measurement group_id="B3" value="41.95" spread="11.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="135"/>
                    <count group_id="B2" value="135"/>
                    <count group_id="B3" value="270"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="223"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>All randomized participants with ethnicity data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="127"/>
                    <count group_id="B2" value="128"/>
                    <count group_id="B3" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="223"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="135"/>
                    <count group_id="B2" value="135"/>
                    <count group_id="B3" value="270"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="211"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Discontinued Due to Adverse Event</title>
        <description>Adverse Event: Any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
A summary of other non-serious AEs, and all SAE's, regardless of causality, is reported in the Adverse Events section.</description>
        <time_frame>Baseline through Month 12</time_frame>
        <population>All randomized participants who received at least one dose of study drug. There were 6 participants in the 120 mg group who discontinued after receiving loading dose of 240mg, these participants were moved to 240mg group for AE analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Galcanezumab 120 mg</title>
            <description>Participants received a loading dose of 240 mg galcanezumab at first dosing visit followed by 120 mg galcanezumab once a month by subcutaneous injection 11 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 240 mg</title>
            <description>Participants received 240 mg of galcanezumab once a month by subcutaneous injection for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Discontinued Due to Adverse Event</title>
          <description>Adverse Event: Any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
A summary of other non-serious AEs, and all SAE's, regardless of causality, is reported in the Adverse Events section.</description>
          <population>All randomized participants who received at least one dose of study drug. There were 6 participants in the 120 mg group who discontinued after receiving loading dose of 240mg, these participants were moved to 240mg group for AE analysis.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.65"/>
                    <measurement group_id="O2" value="4.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Galcanezumab</title>
        <description>Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Galcanezumab</description>
        <time_frame>Baseline through Month 12</time_frame>
        <population>Zero participants analyzed. AUC data was not collected as AUC was not pre-specified in protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Galcanezumab 120 mg</title>
            <description>Participants received a loading dose of 240 mg galcanezumab at first dosing visit followed by 120 mg galcanezumab once a month by subcutaneous injection for 11 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 240 mg</title>
            <description>Participants received 240 mg of galcanezumab once a month by subcutaneous injection for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Galcanezumab</title>
          <description>Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Galcanezumab</description>
          <population>Zero participants analyzed. AUC data was not collected as AUC was not pre-specified in protocol.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Concentrations of Galcanezumab</title>
        <description>Serum Concentrations of Galcanezumab.</description>
        <time_frame>Month 12</time_frame>
        <population>All randomized participants with measurable serum concentrations at month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Galcanezumab 120 mg</title>
            <description>Participants received a loading dose of 240 mg galcanezumab at first dosing visit followed by 120 mg galcanezumab once a month by subcutaneous injection for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 240 mg</title>
            <description>Participants received 240 mg of galcanezumab once a month by subcutaneous injection for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentrations of Galcanezumab</title>
          <description>Serum Concentrations of Galcanezumab.</description>
          <population>All randomized participants with measurable serum concentrations at month 12.</population>
          <units>Nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16500" spread="8370"/>
                    <measurement group_id="O2" value="31600" spread="15900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP)</title>
        <description>Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP)</description>
        <time_frame>Month 12</time_frame>
        <population>All randomized participants with measurable plasma concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>Galcanezumab 120 mg</title>
            <description>Participants received a loading dose of 240 mg galcanezumab at first dosing visit followed by 120 mg galcanezumab once a month by subcutaneous injection for 11 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 240 mg</title>
            <description>Participants received 240 mg of galcanezumab once a month by subcutaneous injection for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP)</title>
          <description>Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP)</description>
          <population>All randomized participants with measurable plasma concentration.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.74" spread="1.07"/>
                    <measurement group_id="O2" value="3.85" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Developing Anti-Drug Antibodies to Galcanezumab</title>
        <description>A Treatment Emergent Anti-drug Antibody (TE ADA) evaluable participant is considered to be TE ADA+ if the participant has at least one post-baseline titer that is a 4-fold or greater increase in titer from baseline measurement. If baseline result is ADA Not Present, then the participant is TE ADA+ if there is at least one post-baseline result of ADA Present with titer &gt;= 1: 20 (treatment-induced).
There were 6 participants in the 120 mg arm who discontinued after receiving loading dose of 240mg, these participants were moved to 240mg arm for safety analysis.</description>
        <time_frame>Month 1 through Month 12</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline evaluable data for TE ADA.</population>
        <group_list>
          <group group_id="O1">
            <title>Galcanezumab 120 mg</title>
            <description>Participants received a loading dose of 240 mg galcanezumab at first dosing visit followed by 120 mg galcanezumab once a month by subcutaneous injection for 11 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 240 mg</title>
            <description>Participants received 240 mg of galcanezumab once a month by subcutaneous injection for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Developing Anti-Drug Antibodies to Galcanezumab</title>
          <description>A Treatment Emergent Anti-drug Antibody (TE ADA) evaluable participant is considered to be TE ADA+ if the participant has at least one post-baseline titer that is a 4-fold or greater increase in titer from baseline measurement. If baseline result is ADA Not Present, then the participant is TE ADA+ if there is at least one post-baseline result of ADA Present with titer &gt;= 1: 20 (treatment-induced).
There were 6 participants in the 120 mg arm who discontinued after receiving loading dose of 240mg, these participants were moved to 240mg arm for safety analysis.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline evaluable data for TE ADA.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.40"/>
                    <measurement group_id="O2" value="7.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>TE ADA Positive (TE ADA+)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.215</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Mean Change From Baseline in the Number of Migraine Headache Days (MHD)</title>
        <description>MHD: A calendar day on which a migraine headache or probable migraine headache occurred. Overall mean is derived from the average of months 1 to 12 from MMRM model. Least squares mean (LSMean) was calculated using mixed model repeated measures (MMRM) model with treatment, pooled investigative site, month, and treatment by month, baseline, and baseline by month as fixed effects.</description>
        <time_frame>Baseline, Month 1 through Month 12</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline &amp; at least one post baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Galcanezumab 120 mg</title>
            <description>Participants received a loading dose of 240 mg galcanezumab at first dosing visit followed by 120 mg galcanezumab once a month by subcutaneous injection for 11 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 240 mg</title>
            <description>Participants received 240 mg of galcanezumab once a month by subcutaneous injection for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Mean Change From Baseline in the Number of Migraine Headache Days (MHD)</title>
          <description>MHD: A calendar day on which a migraine headache or probable migraine headache occurred. Overall mean is derived from the average of months 1 to 12 from MMRM model. Least squares mean (LSMean) was calculated using mixed model repeated measures (MMRM) model with treatment, pooled investigative site, month, and treatment by month, baseline, and baseline by month as fixed effects.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline &amp; at least one post baseline value.</population>
          <units>Migraine Headache Days per Month</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.61" spread="0.34"/>
                    <measurement group_id="O2" value="-6.47" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.60</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-0.86</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.46</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.76</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Mean Change From Baseline in the Number of Headache Days</title>
        <description>Headache Day: A calendar day on which any type of headache occurred (including migraine, probable migraine, and non-migraine headache).
Overall mean is derived from the average of months 1 to 12 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled investigative site, month, and treatment by month, baseline, and baseline by month as fixed effects.</description>
        <time_frame>Baseline, Month 1 through Month 12</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline &amp; at least one post baseline Value.</population>
        <group_list>
          <group group_id="O1">
            <title>Galcanezumab 120 mg</title>
            <description>Participants received a loading dose of 240 mg galcanezumab at first dosing visit followed by 120 mg galcanezumab once a month by subcutaneous injection for 11 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 240 mg</title>
            <description>Participants received 240 mg of galcanezumab once a month by subcutaneous injection for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Mean Change From Baseline in the Number of Headache Days</title>
          <description>Headache Day: A calendar day on which any type of headache occurred (including migraine, probable migraine, and non-migraine headache).
Overall mean is derived from the average of months 1 to 12 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled investigative site, month, and treatment by month, baseline, and baseline by month as fixed effects.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline &amp; at least one post baseline Value.</population>
          <units>Headache Days per Month</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.17" spread="0.30"/>
                    <measurement group_id="O2" value="-2.09" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.835</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.41</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.72</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Overall Reduction From Baseline â‰¥50% in Monthly Migraine Headache Days</title>
        <description>Migraine Headache Day: A calendar day on which a migraine headache or probable migraine headache occurred.
Overall percentage of participants with a given response rate were estimated from the generalized linear mixed models (GLIMMIX) model.</description>
        <time_frame>Baseline, Month 1 through Month 12</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline &amp; at least one post baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Galcanezumab 120 mg</title>
            <description>Participants received a loading dose of 240 mg galcanezumab at first dosing visit followed by 120 mg galcanezumab once a month by subcutaneous injection for 11 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 240 mg</title>
            <description>Participants received 240 mg of galcanezumab once a month by subcutaneous injection for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Overall Reduction From Baseline â‰¥50% in Monthly Migraine Headache Days</title>
          <description>Migraine Headache Day: A calendar day on which a migraine headache or probable migraine headache occurred.
Overall percentage of participants with a given response rate were estimated from the generalized linear mixed models (GLIMMIX) model.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline &amp; at least one post baseline value.</population>
          <units>percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.6"/>
                    <measurement group_id="O2" value="73.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.063</p_value>
            <method>CPLRM</method>
            <method_desc>CPLRM: Categorical pseudo likelihood-based repeated measures model</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.467</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.979</ci_lower_limit>
            <ci_upper_limit>2.197</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Mean Change From Baseline in the Frequency of Medication Use for the Acute Treatment of Migraines or Headaches</title>
        <description>Overall mean is derived from the average of months 1 to 12 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled investigative site, month, and treatment by month, baseline, and baseline by month as fixed effects.</description>
        <time_frame>Baseline, Month 1 through Month 12</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Galcanezumab 120 mg</title>
            <description>Participants received a loading dose of 240 mg galcanezumab at first dosing visit followed by 120 mg galcanezumab once a month by subcutaneous injection for 11 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 240 mg</title>
            <description>Participants received 240 mg of galcanezumab once a month by subcutaneous injection for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Mean Change From Baseline in the Frequency of Medication Use for the Acute Treatment of Migraines or Headaches</title>
          <description>Overall mean is derived from the average of months 1 to 12 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled investigative site, month, and treatment by month, baseline, and baseline by month as fixed effects.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
          <units>Medication Used Days per Month</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.09" spread="0.38"/>
                    <measurement group_id="O2" value="-5.05" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.937</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.96</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Mean Patient Global Impression-Improvement (PGI-I) Score</title>
        <description>The Patient Global Impression of Improvement (PGI -I) scale is a participant-rated instrument that measures the participants own global impression of their symptom improvement. The participant was instructed as follows: &quot;Mark the box that best describes your migraine headache condition since you started taking this medicine.&quot; Response options were on a 7-point scale in which a score of 1 indicates that the participant's condition is &quot;very much better,&quot; a score of 4 indicates that the participant has experienced &quot;no change,&quot; and a score of 7 indicates that the participant is &quot;very much worse.&quot; Overall mean is derived from the average of months 1 to 12 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled investigative site, month, and treatment by month, baseline PGI-S, and baseline PGI-S by month as fixed effects.</description>
        <time_frame>Month 1 through Month 12</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had at least one post baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Galcanezumab 120 mg</title>
            <description>Participants received a loading dose of 240 mg galcanezumab at first dosing visit followed by 120 mg galcanezumab once a month by subcutaneous injection for 11 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 240 mg</title>
            <description>Participants received 240 mg of galcanezumab once a month by subcutaneous injection for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Mean Patient Global Impression-Improvement (PGI-I) Score</title>
          <description>The Patient Global Impression of Improvement (PGI -I) scale is a participant-rated instrument that measures the participants own global impression of their symptom improvement. The participant was instructed as follows: &quot;Mark the box that best describes your migraine headache condition since you started taking this medicine.&quot; Response options were on a 7-point scale in which a score of 1 indicates that the participant's condition is &quot;very much better,&quot; a score of 4 indicates that the participant has experienced &quot;no change,&quot; and a score of 7 indicates that the participant is &quot;very much worse.&quot; Overall mean is derived from the average of months 1 to 12 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled investigative site, month, and treatment by month, baseline PGI-S, and baseline PGI-S by month as fixed effects.</description>
          <population>All randomized participants who received at least one dose of study drug and had at least one post baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.18" spread="0.08"/>
                    <measurement group_id="O2" value="1.99" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.073</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-0.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.40</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Mean Change From Baseline on the Migraine Disability Assessment Test (MIDAS) Total Score</title>
        <description>The MIDAS is a participant-rated scale which was designed to quantify headache-related disability over a 3-month period. This instrument consists of five items that reflect the number of days reported as missing or with reduced productivity at work or home, and the number of days of missed social events. Each item has a numeric response range from 0 to 90 days, if days are missed from work or home they are not counted as days with reduced productivity at work or home. The numeric responses are summed to produce a total score ranging from 0 to 270, in which a higher value is indicative of more disability. Overall mean is derived from the average of months 1 to 12 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled investigative site, month, and treatment by month, baseline, and baseline by month.</description>
        <time_frame>Baseline, Month 1 through Month 12</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Galcanezumab 120 mg</title>
            <description>Participants received a loading dose of 240 mg of galcanezumab at first dosing visit followed by 120 mg galcanezumab once a month by subcutaneous injection for 11 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 240 mg</title>
            <description>Participants received 240 mg of galcanezumab once a month by subcutaneous injection for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Mean Change From Baseline on the Migraine Disability Assessment Test (MIDAS) Total Score</title>
          <description>The MIDAS is a participant-rated scale which was designed to quantify headache-related disability over a 3-month period. This instrument consists of five items that reflect the number of days reported as missing or with reduced productivity at work or home, and the number of days of missed social events. Each item has a numeric response range from 0 to 90 days, if days are missed from work or home they are not counted as days with reduced productivity at work or home. The numeric responses are summed to produce a total score ranging from 0 to 270, in which a higher value is indicative of more disability. Overall mean is derived from the average of months 1 to 12 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled investigative site, month, and treatment by month, baseline, and baseline by month.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.58" spread="2.11"/>
                    <measurement group_id="O2" value="-32.67" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.747</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>0.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.82</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.65</ci_lower_limit>
            <ci_upper_limit>6.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Mean Change From Baseline on the Migraine-Specific Quality of Life Questionnaire (MSQ) Version 2.1</title>
        <description>MSQv2.1 is a health status instrument,with a 4-week recall period, developed to address physical &amp; emotional limitations of specific concern to individuals with migraine. Addressing the impact of migraine on work or daily activities, relationships with family &amp; friends, leisure time, productivity, concentration, energy, tiredness &amp; feelings.It consists of 14 items addressing 3 domains:(1)Role Function-Restrictive (items 1-7);(2)Role Function- Preventive (items 8-11);&amp;(3)Emotional Function (items 12-14).Response options range from &quot;none of the time&quot; (value 1) to &quot;all of the time&quot; (value 6), &amp; are reverse-recoded (value 6 to 1) before the domain scores are calculated. Total raw scores for each domain is the sum of the final item value for all of the items in that domain.After total raw score is computed for each domain &amp; total score, they are transformed to a 0-100 scale with higher scores indicating a better health status &amp; a positive change in scores reflecting functional improvement.</description>
        <time_frame>Baseline, Month 1 through Month 12</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.
Overall mean is derived from the average of months 1 to 12.LSMean was calculated using MMRM model with treatment, pooled investigative site, month, and treatment by month, baseline, and baseline by month as fixed effects.</population>
        <group_list>
          <group group_id="O1">
            <title>Galcanezumab 120 mg</title>
            <description>Participants received a loading dose of 240 mg of galcanezumab at first dosing visit followed by 120 mg galcanezumab once a month by subcutaneous injection for 11 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 240 mg</title>
            <description>Participants received 240 mg of galcanezumab once a month by subcutaneous injection for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Mean Change From Baseline on the Migraine-Specific Quality of Life Questionnaire (MSQ) Version 2.1</title>
          <description>MSQv2.1 is a health status instrument,with a 4-week recall period, developed to address physical &amp; emotional limitations of specific concern to individuals with migraine. Addressing the impact of migraine on work or daily activities, relationships with family &amp; friends, leisure time, productivity, concentration, energy, tiredness &amp; feelings.It consists of 14 items addressing 3 domains:(1)Role Function-Restrictive (items 1-7);(2)Role Function- Preventive (items 8-11);&amp;(3)Emotional Function (items 12-14).Response options range from &quot;none of the time&quot; (value 1) to &quot;all of the time&quot; (value 6), &amp; are reverse-recoded (value 6 to 1) before the domain scores are calculated. Total raw scores for each domain is the sum of the final item value for all of the items in that domain.After total raw score is computed for each domain &amp; total score, they are transformed to a 0-100 scale with higher scores indicating a better health status &amp; a positive change in scores reflecting functional improvement.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.
Overall mean is derived from the average of months 1 to 12.LSMean was calculated using MMRM model with treatment, pooled investigative site, month, and treatment by month, baseline, and baseline by month as fixed effects.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.27" spread="1.16"/>
                    <measurement group_id="O2" value="30.25" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Function-Restrictive Domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.55" spread="1.20"/>
                    <measurement group_id="O2" value="33.40" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Function-Preventive Domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.08" spread="1.11"/>
                    <measurement group_id="O2" value="23.33" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Function Domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.92" spread="1.35"/>
                    <measurement group_id="O2" value="32.01" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total Score</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.203</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>1.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.07</ci_lower_limit>
            <ci_upper_limit>5.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Role Function-Restrictive Domain Score</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.247</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>1.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.59</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.29</ci_lower_limit>
            <ci_upper_limit>4.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Role Function-Preventive Domain Score</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.399</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>1.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.49</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.67</ci_lower_limit>
            <ci_upper_limit>4.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Emotional Function Domain Score</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.88</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>3.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.80</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>6.64</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Positive Responses on Patient Satisfaction With Medication Questionnaire-Modified (PSMQ-M)</title>
        <description>The PSMQ-M is a self-rated scale which measures participants level of satisfaction with study medication.The scale has been modified for use in this study, assessing 3 items related to the clinical trial treatment over the past 4 weeks: satisfaction, preference, and side effects. Satisfaction responses range from &quot;very unsatisfied&quot; to &quot;very satisfied&quot; with the current treatment. Preference compares the current study medication to previous medications, with responses from &quot;much rather prefer my previous medication&quot; to &quot;much rather prefer the medication administered to me during the study&quot;.</description>
        <time_frame>Baseline through Month 12</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had month 12 PSMQ-M measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Galcanezumab 120 mg</title>
            <description>Participants received a loading dose of 240 mg galcanezumab at first dosing visit followed by 120 mg galcanezumab once a month by subcutaneous injection for 11 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 240 mg</title>
            <description>Participants received 240 mg of galcanezumab once a month by subcutaneous injection for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Positive Responses on Patient Satisfaction With Medication Questionnaire-Modified (PSMQ-M)</title>
          <description>The PSMQ-M is a self-rated scale which measures participants level of satisfaction with study medication.The scale has been modified for use in this study, assessing 3 items related to the clinical trial treatment over the past 4 weeks: satisfaction, preference, and side effects. Satisfaction responses range from &quot;very unsatisfied&quot; to &quot;very satisfied&quot; with the current treatment. Preference compares the current study medication to previous medications, with responses from &quot;much rather prefer my previous medication&quot; to &quot;much rather prefer the medication administered to me during the study&quot;.</description>
          <population>All randomized participants who received at least one dose of study drug and had month 12 PSMQ-M measurement.</population>
          <units>percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Satisfaction: Very satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.78"/>
                    <measurement group_id="O2" value="58.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction: Somewhat satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.89"/>
                    <measurement group_id="O2" value="15.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Preference: Much prefer study medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67"/>
                    <measurement group_id="O2" value="63.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Preference: Prefer study medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.22"/>
                    <measurement group_id="O2" value="17.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Side effects: Much less side effects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67"/>
                    <measurement group_id="O2" value="50.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Side effects: Less side effects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.44"/>
                    <measurement group_id="O2" value="30.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participant Visits With Positive Reponses by Device Type Subcutaneous Administration Assessment Questionnaire Q1, Q3-Q12</title>
        <description>The SQAAQ is a self-administered questionnaire that provides an assessment of ease of use and confidence with using a device to administer a subcutaneous injection of study drug. Participants will respond to questionnaire items using a 7-point Likert scale (from &quot;Strongly Disagree&quot; to &quot;Strongly Agree&quot;) shortly after the injection. If a caregiver administers the injection, the participants should be prepared to provide the caregiver's ratings of the questions.strongly agree &amp; agree are considered as positive responses.</description>
        <time_frame>Baseline through Month 12</time_frame>
        <population>All randomized participants who switched from pre-filled syringe and received at least one dose of study drug by autoinjector.</population>
        <group_list>
          <group group_id="O1">
            <title>Galcanezumab 120 mg</title>
            <description>Participants received a loading dose of 240 mg galcanezumab at first dosing visit followed by 120 mg galcanezumab once a month by subcutaneous injection for 11 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 240 mg</title>
            <description>Participants received 240 mg of galcanezumab once a month by subcutaneous injection for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participant Visits With Positive Reponses by Device Type Subcutaneous Administration Assessment Questionnaire Q1, Q3-Q12</title>
          <description>The SQAAQ is a self-administered questionnaire that provides an assessment of ease of use and confidence with using a device to administer a subcutaneous injection of study drug. Participants will respond to questionnaire items using a 7-point Likert scale (from &quot;Strongly Disagree&quot; to &quot;Strongly Agree&quot;) shortly after the injection. If a caregiver administers the injection, the participants should be prepared to provide the caregiver's ratings of the questions.strongly agree &amp; agree are considered as positive responses.</description>
          <population>All randomized participants who switched from pre-filled syringe and received at least one dose of study drug by autoinjector.</population>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Number of participant visits</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of participant visits</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="899"/>
                <count group_id="O2" value="1032"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-filled Syringe : Easy to learn how to use</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Number of participant visits</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="646"/>
                    <count group_id="O2" value="751"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="611"/>
                    <measurement group_id="O2" value="688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-filled Syringe : Easy to hold in hand</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Number of participant visits</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="646"/>
                    <count group_id="O2" value="751"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="589"/>
                    <measurement group_id="O2" value="660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-filled Syringe : Easy to inject my dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Number of participant visits</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="645"/>
                    <count group_id="O2" value="751"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="580"/>
                    <measurement group_id="O2" value="659"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-filled Syringe : Easy to know dose is complete</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Number of participant visits</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="646"/>
                    <count group_id="O2" value="751"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="615"/>
                    <measurement group_id="O2" value="703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-filled Syringe: Easy to store device in fridge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Number of participant visits</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="625"/>
                    <count group_id="O2" value="726"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="536"/>
                    <measurement group_id="O2" value="630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-filled Syringe : Easy to remove needle shield</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Number of participant visits</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="646"/>
                    <count group_id="O2" value="751"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="610"/>
                    <measurement group_id="O2" value="699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-filled Syringe : Easy to pickup</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Number of participant visits</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="646"/>
                    <count group_id="O2" value="751"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="610"/>
                    <measurement group_id="O2" value="693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-filled Syringe : overall, easy to use</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Number of participant visits</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="646"/>
                    <count group_id="O2" value="751"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="600"/>
                    <measurement group_id="O2" value="663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-filled Syringe:Dvc is stable against skin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Number of participant visits</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="646"/>
                    <count group_id="O2" value="744"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="590"/>
                    <measurement group_id="O2" value="652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-filled Syringe:Confident in ability to use</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Number of participant visits</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="646"/>
                    <count group_id="O2" value="751"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="580"/>
                    <measurement group_id="O2" value="654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-filled Syringe : Confident my dose is complete</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Number of participant visits</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="646"/>
                    <count group_id="O2" value="751"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="618"/>
                    <measurement group_id="O2" value="708"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoinjector : Easy to learn how to use</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Number of participant visits</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250"/>
                    <measurement group_id="O2" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoinjector : Easy to hold in hand</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Number of participant visits</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247"/>
                    <measurement group_id="O2" value="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoinjector : Easy to inject my dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Number of participant visits</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                    <measurement group_id="O2" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoinjector : Easy to know dose is complete</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Number of participant visits</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241"/>
                    <measurement group_id="O2" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoinjector : Easy store device in fridge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Number of participant visits</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="247"/>
                    <count group_id="O2" value="278"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230"/>
                    <measurement group_id="O2" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoinjector : Easy to remove needle shield</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Number of participant visits</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250"/>
                    <measurement group_id="O2" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoinjector : Easy to pickup</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Number of participant visits</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251"/>
                    <measurement group_id="O2" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoinjector : Overall, easy to use</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Number of participant visits</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251"/>
                    <measurement group_id="O2" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoinjector : Dvc is stable against skin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Number of participant visits</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244"/>
                    <measurement group_id="O2" value="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoinjector : Confident in ability to use</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Number of participant visits</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247"/>
                    <measurement group_id="O2" value="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoinjector : Confident my dose is complete</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Number of participant visits</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244"/>
                    <measurement group_id="O2" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 421 days</time_frame>
      <desc>All randomized participants. There were 6 participants in the 120 mg open label arm who discontinued after receiving loading dose of 240mg, these participants were moved to 240mg arm for AE analysis.
Per protocol, AE analysis was planned per treatment regimen received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Galcanezumab 120 mg - Open Label Phase</title>
          <description>Participants received a loading dose of 240 mg galcanezumab at first dosing visit followed by 120 mg Galcanezumab once a month by subcutaneous injection for 11 months.</description>
        </group>
        <group group_id="E2">
          <title>Galcanezumab 240 mg - Open Label Phase</title>
          <description>Participants received 240 mg of galcanezumab once a month by subcutaneous injection for 12 months.</description>
        </group>
        <group group_id="E3">
          <title>Galcanezumab 120 mg - Post-treatment Phase</title>
          <description>Participants did not receive any intervention.</description>
        </group>
        <group group_id="E4">
          <title>Galcanezumab 240 mg - Post-treatment Phase</title>
          <description>Participants did not receive any intervention.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Infective aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Pineal gland cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic ovarian cyst</sub_title>
                <description>All randomized female participants. There were 6 female participants in the 120 mg arm who discontinued after receiving loading dose of 240mg, these participants were moved to 240mg arm for AE analysis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Uterine leiomyoma embolisation</sub_title>
                <description>All randomized female participants. There were 6 female participants in the 120 mg arm who discontinued after receiving loading dose of 240mg, these participants were moved to 240mg arm for AE analysis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="129"/>
                <counts group_id="E2" events="15" subjects_affected="9" subjects_at_risk="141"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="129"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="141"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="20" subjects_affected="9" subjects_at_risk="129"/>
                <counts group_id="E2" events="19" subjects_affected="9" subjects_at_risk="141"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="148" subjects_affected="22" subjects_at_risk="129"/>
                <counts group_id="E2" events="272" subjects_affected="28" subjects_at_risk="141"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="48" subjects_affected="15" subjects_at_risk="129"/>
                <counts group_id="E2" events="32" subjects_affected="13" subjects_at_risk="141"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="129"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="141"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="129"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="141"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="129"/>
                <counts group_id="E2" events="23" subjects_affected="21" subjects_at_risk="141"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="27" subjects_affected="21" subjects_at_risk="129"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="141"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="129"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="129"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="141"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="129"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="141"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="129"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="129"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="141"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <description>All randomized male participants.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

